We are a pioneering biopharmaceutical company, focused on the discovery, rational design and initial clinical development of drugs. These compounds are all based on a novel therapeutic approach: Membrane Lipid Therapy (MLT), or melitherapy for short, which targets membrane lipids, instead of acting directly on proteins or DNA as most medicines do.
We created the company in 2006 as a spin-off from the University of the Balearic Islands (UIB) in Mallorca, Spain. Our goal is for melitherapy drugs to become reference treatments worldwide for serious diseases with unmet medical needs, such as glioblastoma and other aggressive cancers, as well as neurodegenerative, metabolic and inflammatory diseases. This will improve the clinical outcome and quality of life of many patients worldwide.
We carry out translational research with the goal of delivering treatments for serious illnesses which lack effective therapies. This includes rare conditions and those which are currently incurable, or which have poor prognoses with few treatment options, such as pediatric brain cancer (glioma), APBD, Down syndrome or spastic paraplegia.
We set up Laminar Pharma in 2006 to develop breakthrough inventions patented with the University of the Balearic Islands (UIB). We are proud to bring an entrepreneurial spirit to the Innovation and Technology Park (ParcBIT) in our home island of Mallorca, Spain, where the main economic activity is tourism.
Every year we supervise and work alongside PhD candidates and postdoctoral researchers who carry out their research projects at Laminar Pharma. Through this mutually beneficial mentoring scheme, we aim to provide opportunities for young scientists to develop their career in the industrial sector.
We believe that companies must be useful to the public, so we apply ourselves to improve the quality of life of all citizens. Our commitment is to our employees, to our stakeholders and to the patients who receive our drugs – but also to the community at large, as we push for a prosperous, well cared-for society.
The Board of Directors holds non-transferable powers which are legally reserved for its members’ knowledge, as well as competencies required for responsible supervision of the company. Members approve the strategic and business plans, as well as the management goals and annual budgets. The Board determines the general policies and strategies of the Company, such as the determination of the corporate governance policy of Laminar Pharma or the responsible management policy. It also supervises the operation of any committees which have been set up and the performance of the delegate bodies.
In their decision-making, Members of the Board are guided by the Group’s corporate interest. The Board of Directors will ensure that the Company faithfully complies with current legislation, follows the uses and good practices of the sectors or countries where it operates and observes any principles of social responsibility that it has voluntarily accepted.
Bernat Soria – (Independent)
Antonio López – (Independent)
Mar Gallardo – (Independent)
Prof. Pablo V. Escribá, PhD.
CEO & Founder
He is Professor of Cell Biology at the University of the Balearic Islands (UIB, Mallorca, Spain) and the main promoter of Laminar Pharma. He has more than twenty years of successful experience as a scientist and researcher, and he has held senior research stages in USA (New York, Kansas City and Charleston), Switzerland (Geneve) and Hungary (Szeged).
``My professional interest is to discover and develop therapies for various types of patients. Although historically my career has focused on drugs for highly prevalent diseases, such as cancer, Alzheimer's disease or neuropathic pain, for some years I have been committed to rare and pediatric diseases. They are groups which have received less attention from our society to attend to their clinical needs because the profits in these areas are lower. However, it is possible to reconcile social needs with the profit that a company in the pharmaceutical sector should obtain, by taking advantage of the benefits offered by different countries. My goal is to develop innovative products based on leading-edge science for highly effective and safe medicines. My principles are: If someone has done it before, I can do it too – if no one has done it, I can be the first.``
Victoria Llado, PhD.
General Manager USA
Dr. Llado holds a degree in Biology (UIB) and in Biochemistry (UIB) and a PhD in in Molecular Biology (UIB). After postdoctoral fellow research positions at the Gastro-Intestinal Unit of MGH, Harvard Medical School (Boston, MA, USA) at the Sanford-Burnham Medical Research Institute (San Diego, CA, USA) and at the UIB (with a grant from the Asociación Española Contra el Cancer, AECC), she joined Laminar Pharma as head of the laboratory facilities and CSO of Laminar Pharma in December 2018.
Paula Fernandez, PhD.
Dr. Fernandez has a degree in Biochemistry (University of Oviedo) and a PhD in Biochemistry and Molecular Biology (University of Oviedo). After a brief period at the UIB, she joined Laminar Pharma in November 2013, after obtaining a Torres Quevedo contract. Her research is developed mainly in the fields of proteomics and molecular biology. She is leading the basic and applied research aimed at further elucidating 2OHOA’s mechanism of action in oncology and at the identification and development of biomarkers to support the clinical development of 2OHOA.
Armando Cuesta, PhD, MD.
Medical director of Laminar since 2021. Dr Armando Cuesta has a degree in Medicine and Surgery since 2009 from the Complutense University of Madrid, where he also completed his doctoral thesis. He completed a post-doctorate in the Department of Neurosciences at the Icahn School of Medicine at Mount Sinai, New York. Dr Cuesta has practiced as a physician in American hospitals (Montefiore Medical Center, Jacobi Medical Center) and worked in the development of clinical trials for the pharmaceutical industry in the United States. He is co-founder of Ilana Capital and currently directs Abante Biotech, an investment fund in the health sector.
Antonio J. Gonzalez
Antonio González joined Laminar in 2010 and participated in the design and development of the project’s business model. He holds a diploma in Economic and Business Sciences and a bachelor’s degree in Business Administration and Management, and he is also a qualified technician in Foreign Trade. He has 25 years of previous experience in auditing and consulting, transportation and import-export.
Head of Finance of the company since 2020, previously exercising functions as Finance Manager at international groups related to the tourism sector, such as Thomas Cook Airlines, TUI / Hotelbeds Group or Riu Hotels. He was an account auditor at KPMG. Diploma in Economic and Business Sciences and with the title of Chartered Accountant granted by the Official Register of Accounts Auditors. He is currently undertaking the Advanced Program of General Management at the Instituto de Empresa.
Catalina Ana Rossello, PhD.
Head of CMC
Head of Chemistry Manufacturing and Controls at Laminar since 2020, where she joined as senior scientist in 2016. She holds a degree in Biology and a degree in Biochemistry from the University of the Balearic Islands, and a PhD in Molecular Biology from the Autonomous University of Madrid. With a background in developmental biology and cell division, she occupied research positions at Lund University (Sweden) and at the UIB (with a European FP7 Marie Curie grant). In 2019, she became head of the clinical R&D scientific area at Laminar and, the year after, Head of CMC. CMC department is responsible for all drug substance (API) and drug product (DP) activities from preclinical development through clinical supplies for Phase 3 registration studies (cGMP manufacture and supply chain of API and DP in support of ongoing clinical programs) together with identification, selection and management of Contract Manufacturing Organizations (CMOs) and collaboration in the writing and reviewing of documents for regulatory submissions.
Adrian G. McNicholl, PhD.
Dr. McNicholl holds a PhD. in Medicine and Surgery; formerly a post-doctoral researcher at CIBERehd, he has participated in over 60 traslational research projects including the design and coordination of several clinical trials, producing over 40 indexed publications (H-index= 21). He founded in 2013 and has been the Scientific Director (until 2019) of the non-profit Spanish Platform for Collaborative Research in Gastroenterology (AEG‐REDCap) with more than 70 projects, and 1,600 researchers in 45 countries. He has coordinated several courses and books on evidence based clinical practice and traslational research, and received over 10 international awards and grants for his oral and poster presentations.
Maria Sola Gil
Strategic Drug Development Director
Director of Corporate Strategy at Laminar since 2020, where she arrived as an external advisor, and Director of the Biotechnology area at Nowture. She studied Biotechnology at the University of León and a Master’s in Research, Development and Innovation of Medicines at the University of Navarra. After a period of research in the field of genetic engineering, producing of monoclonal antibodies at the University of New South Wales (Sydney, Australia), she returned to Spain, Laboratorios Cinfa, to develop a new line of business in cosmetics, working in pharmaceutical development, innovation and, later, in marketing. She joined the Cinfa Biotech team in 2013 as Project Manager of the first biosimilar biotechnological drug for the company. She was responsible for its commercial launch in Europe in 2019 and later in the rest of the world, then she became part of the Mundipharma Biologics team as Global Product Lead, when Cinfa Biotech was acquired by Mundipharma (UK), in 2018.
Richard J. Taylor, PhD.
Head of Regulatory and Medical Affairs
Dr. Taylor has extensive large pharmaceutical company experience. Formerly Head of International Clinical and Regulatory Affairs with Zeneca Pharmaceuticals (now AstraZeneca), Dr. Taylor has held management positions with Fisons Pharmaceuticals (now part of Aventis) and The Wellcome Research Laboratories (now part of Glaxo SmithKline). Since 2001 he is Managing Consultant & Projects Director at The Medical & Regulatory Partnership Ltd (TMRP), a drug development consultancy specializing in global regulatory services.
Clinical Trial manager
Member of the Board of Directors since 2019 and Corporate Director since 2020. He is a founding partner of Nowture, a company dedicated to financing and commercializing transformative projects in biotechnology and life sciences, with the purpose of changing the world by improving people’s lives. He has successfully promoted more than a dozen projects in the pharma and biotech industries. He has held positions of responsibility within the pharma industry, with an international outlook, catalyzing its organic and inorganic growth. Previously, he performed management duties in the assurance division within consulting firm PwC. He has a degree in Business Administration and Management from the University of Navarra, and postgraduate degrees in Senior Management and Strategic Leadership from Esade and The Wharton School (University of Pennsylvania)
Prof. Manuel Illescas, PhD.
He is a specialist in patent prosecution in Spain, as qualified European Patent Attorney EPA) before the European Patent Office (EPO) and via Patent Cooperation Treaty (PCT), with more than 30 years of experience, especially in the following technical sectors: pharmaceutical, chemical, environmental, biomedical and, above all, in the biotechnological sector. He has held senior executive positions in several patent managing companies, including MIAPatents, González-Bueno & Illescas, and ELZABURU, along with Venture Capital companies (Cross Road Biotech). He is also authorized to act as representative for trademarks matters before European Union Office for Intellectual Property (EUIPO), Spanish Patent Office (SPO) and World Intellectual Property Organization (WIPO).
José Javier Muruzabal
José Javier Muruzabal, external manager of Product Development and production processes in Laminar’s Research and Development area. He is in charge of planning protocols, monitoring and evaluating results in formulation of active principles, drug production and analytical methods . He is an expert in GMP and GLP guides, and in the preparation of the IMPD dossier. As a Qualified Person for external quality consulting, he also works at Medalchemy since 2014. He has taught Pharmaceutical Technology at the University of Navarra and at several postgraduate Masters courses, and he is promoter of the contract manufacturing organization Idifarma Desarrollo Farmacéutico. He has extensive experience in evaluating with inspection agencies and in audits of production processes for various biopharmaceutical companies.
Director of Communication
Director of Communications at Laminar since 2020. She has a Master’s in Health Journalism and postgraduate degrees in Clinical Research and Global Health. She brings extensive experience in managing corporate image strategies and product launch plans within the biopharmaceutical and medical technology fields. As an enthusiast of scientific dissemination, she was part of the founding team of the Association of Biotechnology Communicators. She has worked a lot in advocacy projects with associations of patients who suffer orphan diseases and has received recognition from the FEDER for this. She combines business consulting with the promotion of international projects that are innovative in the area of social and health care, focusing on social impact.
Fellow Funders is an independent Spanish firm whose mission is to support SMEs and startups in their expansion and consolidation plans by finding their optimal financing models. Its value proposition The Finance Symphony is a harmony of movements at the service of entrepreneurs, managers and their companies, as well as investors. They offer company valuation through Fair Value, financing rounds or equity crowdfunding using their Crowd Investment platform, financial and strategic counsel via Alternative Assets, and finally guiding clients into the stock markets (BME Growth, Euronext and OTC) with their Capital Markets division.
Regulatory, Business and Clinical strategies
QUALITECFARMA is a CRO that for 20 years has been dedicated to the business of managing highly qualified projects in the areas of clinical research, Monitoring, Data Management, Biostatistics, Pharmacovigilance, Scientific Drafting Regulatory Affairs, Market Access and Corporate Operations for the pharmaceutical industry.
In order to advance our innovative R&D pipeline we are continuously seeking new collaborations. We welcome licensing, partnering and alliances with leading players in the industry who can effectively contribute to bring novel melitherapy-based products to the market and make them available to patients globally.
We have recently joined the Growth segment of the Pre-Market Environment, in a step towards joining the stock market. The Pre-Market Environment (EpM) training program started in 2017 for growing SMEs. This ecosystem connects investors, companies and professionals from official and alternative markets of equities and bonds. We are looking forward to working with private investors and institutions by joining the MAB stock market before the end of 2020.
We are convinced that bringing together passionate and talented people, valuing their work as individuals and teams and giving them freedom to pursue clear, shared goals, breeds success. We believe in “doing well by doing good”.
Our current and near-future needs require expertise in the following areas:
Although we might not currently have staff vacancies available for your profile, feel free to send your CV* at any time and we will consider you for future job openings.
*Please send your resume in English to email@example.com
Laminar Pharma’s head offices and Lab facilities are located at the Balearic Islands Innovation and Technology Park (ParcBIT), just by the University of the Balearic Islands (UIB), in Mallorca, Spain. Our US subsidiary in located in the State of Massachusetts (Boston Area).
+34 971 43 98 86
Edificio Naorte, Bloque A,
1ª planta. Puerta 3,
07121 Palma de Mallorca, Baleares (Spain)